Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online April 10, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2007-1009v1
26/6/1414    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shu, Q.
Right arrow Articles by Li, X. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shu, Q.
Right arrow Articles by Li, X. N.
Submitted on November 29, 2007
Accepted on March 24, 2008

CANCER STEM CELLS

Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma

Qin Shu 1, Kwong Kwok Wong 2, Jack M. Su 3, Adekunle M. Adesina 4, Li Tian Yu 1, Yvonne T.M. Tsang 2, Barbara C. Antalffy 4, Patricia Baxter 3, Laszlo Perlaky 3, Jianhua H. Yang 3, Robert C. Dauser 5, Murali Chintagumpala 3, Susan M. Blaney 3, Ching C. Lau 3, Xiao Nan Li 1*

1 Laboratory of Molecular Neuro-Oncology, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.
2 Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX. Depatment of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
3 Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.
4 Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.
5 Neurosurgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.

* To whom correspondence should be addressed. E-mail: xiaonan{at}bcm.tmc.edu.


   Abstract

Recent identification of cancer stem cells in medulloblastoma (MB) and high-grade glioma has stimulated an urgent need for animal models that will not only replicate the biology of these tumors, but also preserve their cancer stem cell pool. We hypothesize that direct injection of fresh surgical specimen of MB and high-grade glioma tissues into anatomically equivalent locations in immune-deficient mouse brains will facilitate the formation of clinically accurate xenograft tumors by allowing brain tumor stem cells, together with their non-stem tumor and stromal cells, to grow in a microenvironment that is the closest to human brains. Eight of the 14 MBs (57.1%) and two of the three high-grade gliomas (66.7%) in this study developed transplantable (up to 12 passages) xenografts in mouse cerebellum and cerebrum, respectively. These xenografts are patient specific, replicating the histopathologic, immunophenotypic, invasive/metastatic, and major genetic (analyzed with 10K SNP array) abnormalities of the original tumors. The xenograft tumor cells have also been successfully cryopreserved for long-term preservation of tumorigenicity, ensuring a sustained supply of the animal models. More importantly, the CD133+ tumor cells, ranging from 0.2%–10.4%, were preserved in all the xenograft models following repeated orthotopic subtransplantations in vivo. The isolated CD133+ tumor cells formed neurospheres and displayed multi-lineage differentiation capabilities in vitro. In summary, our study demonstrates that direct orthotopic transplantation of fresh primary tumor cells is a powerful approach in developing novel clinical relevant animal models that can reliably preserve CD133+ tumor cell pools even during serial in vivo subtransplantations.

______________________________________________________________________________

Author contributions: Q.S.: Collection and/or assembly of data, data analysis and interpretation, manuscript writing; K.K.W.: Collection and/or assembly of data, data analysis and interpretation; J.M.S.: Provision of study material or patients, data analysis and interpretation; A.M.A.: Provision of study material or patients, collection and/or assembly of data, data analysis and interpretation; L.Y.: Collection and/or assembly of data, data analysis and interpretation, manuscript writing; Y.T.M.T.: Collection and/or assembly of data, data analysis and interpretation; B.C.A.: Collection and/or assembly of data, data analysis and interpretation; P.B.: Collection and/or assembly of data, data analysis and interpretation, manuscript writing; L.P.: Provision of study material or patients; J.Y.: Data analysis and interpretation, manuscript writing; R.C.D.: Provision of study material or patients; M.C.: Provision of study material or patients, data analysis and interpretation, manuscript writing; S.M.B.: Provision of study material or patients, data analysis and interpretation, manuscript writing; C.C.L.: Provision of study material or patients, data analysis and interpretation, manuscript writing; X.L.: Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript.

Key Words. medulloblastoma, glioma, orthotopic xenograft model, cancer stem cell




This article has been cited by other articles:


Home page
DMMHome page
A. Gopinathan and D. A. Tuveson
The use of GEM models for experimental cancer therapeutics.
Dis. Model. Mech., September 1, 2008; 1(2-3): 83 - 86.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
Email Content Delivery
Copyright © 2008 by AlphaMed Press.